In phase I trial of hypoxia-responsive CEA CAR-T cell therapy, patients with advanced solid tumors, including NSCLC, showed sustained tumor remission for more than 5 months after high-dose CEA-CAR-T therapy. Here, CEACAM5 is linked to non-small cell lung carcinoma.